The Tyrosine Protein Kinase Lck pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase Lck targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase Lck pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Respiratory, Oncology, Infectious Disease, and Genetic Disorders which include the indications Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Breast Cancer, Influenzavirus A Infections, Coronavirus Disease 2019 (COVID-19) Pneumonia, Von Hippel-Lindau Syndrome, and Hereditary Hemorrhagic Telangiectasia (Osler–Weber–Rendu Disease). It also reviews key players involved in Tyrosine Protein Kinase Lck targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Kinase Lck pipeline targets constitutes close to 12 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, and Preclinical stages are 1, 1, 1, 3, and 5 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Tyrosine Protein Kinase Lck overview
Tyrosine Protein Kinase Lck (LCK) is a member of the Src family of protein tyrosine kinases (PTKs). LCK plays an important role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells and also plays a key role in T-cell antigen receptor (TCR)-linked signal transduction pathways. LCK contains N-terminal sites for myristylation and palmitylation, a PTK domain, and SH2 and SH3 domains which are involved in mediating protein-protein interactions with phosphotyrosine-containing and proline-rich motifs.
For a complete picture of Tyrosine Protein Kinase Lck’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
